ANORO ELLIPTA
Total Payments
$2.3M
Transactions
66,944
Doctors
21,355
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $88,098 | 20 | 8 |
| 2022 | $8,576 | 220 | 133 |
| 2021 | $578,585 | 24,467 | 11,579 |
| 2020 | $1.4M | 38,873 | 13,655 |
| 2019 | $55,902 | 714 | 314 |
| 2018 | $1,410 | 94 | 45 |
| 2017 | $185,348 | 2,556 | 1,986 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1.1M | 66,417 | 49.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $615,650 | 230 | 26.6% |
| Unspecified | $477,484 | 147 | 20.6% |
| Consulting Fee | $63,248 | 60 | 2.7% |
| Travel and Lodging | $12,465 | 84 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $1,400 | 2 | 0.1% |
| Education | $129.00 | 4 | 0.0% |
Payments by Type
General
$1.8M
66,797 transactions
Research
$477,484
147 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| POST-AUTHORISATION SAFETY (PAS) OBSERVATIONAL COHORT STUDY TO QUANTIFY | GlaxoSmithKline, LLC. | $395,423 | 0 |
| THE COMBINATION OF UMECLIDINIUM AND VILANTEROL ENHANCES BRONCHODILATIO | GlaxoSmithKline, LLC. | $78,035 | 0 |
| A 24 MONTH DOUBLE BLIND RANDOMISED PARALLEL GROUP STUDY TO DETERMINE T | GlaxoSmithKline, LLC. | $4,026 | 0 |
Top Doctors Receiving Payments for ANORO ELLIPTA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Internal Medicine | Richmond, KY | $8,589 | 7 |
| , MD | Allergy & Immunology | Colorado Springs, CO | $8,450 | 5 |
| , MD | Critical Care Medicine | Kissimmee, FL | $8,077 | 17 |
| , M.D | Internal Medicine | Rockville, MD | $7,997 | 16 |
| , MD | Pulmonary Disease | Parkersburg, WV | $7,904 | 15 |
| , MD | Critical Care Medicine | Humble, TX | $7,593 | 18 |
| , MD | Pulmonary Disease | Franklin, TN | $7,586 | 8 |
| , MD | Allergy & Immunology | Columbus, GA | $7,479 | 6 |
| , M.D | Internal Medicine | Webster, TX | $7,363 | 12 |
| , M.D | Pulmonary Disease | Gastonia, NC | $7,340 | 13 |
| , M.D | Pulmonary Disease | Saint Louis, MO | $6,808 | 15 |
| , MD | Critical Care Medicine | Stockton, CA | $6,529 | 3 |
| , D.O | Internal Medicine | Linwood, NJ | $6,444 | 13 |
| , MD | Pulmonary Disease | Plano, TX | $6,154 | 17 |
| , MD | Pulmonary Disease | Middletown, DE | $6,137 | 6 |
| , M.D | Internal Medicine | Minneapolis, MN | $5,965 | 6 |
| , M.D | Pulmonary Disease | Chicago, IL | $5,959 | 9 |
| , MD | Pulmonary Disease | Arecibo, PR | $4,963 | 4 |
| , MD | Internal Medicine | Anderson, SC | $4,800 | 2 |
| , MD | Internal Medicine | Williamsville, NY | $4,550 | 4 |
| , M.D | Pulmonary Disease | Great Neck, NY | $4,525 | 30 |
| , MD | Pulmonary Disease | Lodi, NJ | $4,271 | 18 |
| , MD | Pulmonary Disease | New Rochelle, NY | $4,230 | 13 |
| , M.D | Pulmonary Disease | Franklin, IN | $4,126 | 12 |
| , M.D | Pulmonary Disease | Olympia, WA | $4,100 | 23 |
Ad
Manufacturing Companies
- GlaxoSmithKline, LLC. $2.3M
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 21,355
- Transactions 66,944
About ANORO ELLIPTA
ANORO ELLIPTA is a drug associated with $2.3M in payments to 21,355 healthcare providers, recorded across 66,944 transactions in the CMS Open Payments database. The primary manufacturer is GlaxoSmithKline, LLC..
Payment data is available from 2017 to 2023. In 2023, $88,098 was paid across 20 transactions to 8 doctors.
The most common payment nature for ANORO ELLIPTA is "Food and Beverage" ($1.1M, 49.4% of total).
ANORO ELLIPTA is associated with 3 research studies, including "POST-AUTHORISATION SAFETY (PAS) OBSERVATIONAL COHORT STUDY TO QUANTIFY" ($395,423).